$3.61
1.69% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

MaxCyte Inc Stock price

$3.61
+0.04 1.12% 1M
-0.93 20.48% 6M
-1.09 23.19% YTD
-1.04 22.37% 1Y
-5.56 60.63% 3Y
+2.02 126.59% 5Y
+2.02 126.59% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 1.69%
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

Key metrics

Market capitalization $380.79m
Enterprise Value $245.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.38
P/S ratio (TTM) P/S ratio 8.35
P/B ratio (TTM) P/B ratio 1.78
Revenue growth (TTM) Revenue growth 19.85%
Revenue (TTM) Revenue $45.60m
EBIT (operating result TTM) EBIT $-46.31m
Free Cash Flow (TTM) Free Cash Flow $-21.23m
Cash position $153.83m
EPS (TTM) EPS $-0.34
P/E forward negative
P/S forward 10.11
EV/Sales forward 6.51
Short interest 3.11%
Show more

Is MaxCyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MaxCyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a MaxCyte Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a MaxCyte Inc forecast:

Buy
100%

Financial data from MaxCyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
46 46
20% 20%
100%
- Direct Costs 11 11
24% 24%
23%
35 35
19% 19%
77%
- Selling and Administrative Expenses 54 54
10% 10%
117%
- Research and Development Expense 23 23
1% 1%
51%
-42 -42
2% 2%
-92%
- Depreciation and Amortization 4.36 4.36
9% 9%
10%
EBIT (Operating Income) EBIT -46 -46
1% 1%
-102%
Net Profit -36 -36
5% 5%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about MaxCyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MaxCyte Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
Neutral
Seeking Alpha
19 days ago
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
20 days ago
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance.
More MaxCyte Inc News

Company Profile

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Maher Masoud
Employees 143
Founded 1998
Website www.maxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today